ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American Thoracic Society Conference in San Francisco. The abstract is entitled “Development of a Novel ProteaseTag® Activity-based Immunoassay for the specific measurement of neutrophil elastase in clinical samples from patients with respiratory disease”, and will be presented by Dr Kelly Moffitt between 11.45 and 12.45 pm on May 18th, 2016 in the Lab Methodology and Bioengineering session.
The data being presented will summarise the clinical validation of the ProteaseTag® Active NE Immunoassay for the detection and quantification of free NE activity in sputum and bronchoalveolar lavage from patients with chronic respiratory diseases, including COPD and cystic fibrosis. The authors conclude that the Immunoassay has been shown to be superior to kinetic substrate-based assays, revealing correlations between NE and clinical parameters not previously observed.
Dr David Ribeiro, CEO of ProAxsis, said: “The American Thoracic Society has over 15,000 members, and has been holding an annual international conference since 1905. As COPD is one of the key focuses of the Society, we are delighted that data concerning the use of our ProteaseTag® Active Neutrophil Elastase Immunoassay in this patient group and those with other respiratory diseases has been accepted by such a prestigious congress”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
To place an order for the ProteaseTag® Active NE Immunoassay, or for further information, please contact email@example.com